Cardiac and arrhythmic complications in patients with COVID-19

Adriano Nunes Kochi, Ana Paula Tagliari, Giovanni Battista Forleo, Gaetano Michele Fassini, Claudio Tondo, Adriano Nunes Kochi, Ana Paula Tagliari, Giovanni Battista Forleo, Gaetano Michele Fassini, Claudio Tondo

Abstract

In December 2019, the world started to face a new pandemic situation, the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Although coronavirus disease (COVID-19) clinical manifestations are mainly respiratory, major cardiac complications are being reported. Cardiac manifestations etiology seems to be multifactorial, comprising direct viral myocardial damage, hypoxia, hypotension, enhanced inflammatory status, ACE2-receptors downregulation, drug toxicity, endogenous catecholamine adrenergic status, among others. Studies evaluating patients with COVID-19 presenting cardiac injury markers show that it is associated with poorer outcomes, and arrhythmic events are not uncommon. Besides, drugs currently used to treat the COVID-19 are known to prolong the QT interval and can have a proarrhythmic propensity. This review focus on COVID-19 cardiac and arrhythmic manifestations and, in parallel, makes an appraisal of other virus epidemics as SARS-CoV, Middle East respiratory syndrome coronavirus, and H1N1 influenza.

Keywords: COVID-19; SARS-CoV-2; arrhythmia; myocardial damage; myocarditis.

© 2020 Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
Mechanisms and consequences of COVID‐19 myocardial damage. COVID‐19, coronavirus disease

References

    1. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID‐19 in Wuhan, China. JAMA. 2020. 10.1001/jamacardio.2020.0950
    1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‐infected pneumonia in wuhan, China. JAMA. 2020. 10.1001/jama.2020.1585
    1. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020. 10.1093/eurheartj/ehaa190
    1. Sellers SA, Hagan RS, Hayden FG, Fischer WA 2nd. The hidden burden of influenza: a review of the extra‐pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017;11:372‐393.
    1. Alexander LK, Small JD, Edwards S, Baric RS. An experimental model for dilated cardiomyopathy after rabbit coronavirus infection. J Infect Dis. 1992;166:978‐985.
    1. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long‐term implications. Eur Heart J. 2020. 10.1093/eurheartj/ehaa231
    1. Yu CM, Wong RS, Wu EB, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82:140‐144.
    1. Lau ST, Yu WC, Mok NS, Tsui PT, Tong WL, Cheng SW. Tachycardia amongst subjects recovering from severe acute respiratory syndrome (SARS). Int J Cardiol. 2005;100:167‐169.
    1. Pan SF, Zhang HY, Li CS, Wang C. Cardiac arrest in severe acute respiratory syndrome: analysis of 15 cases. Zhonghua Jie He He Hu Xi Za Zhi. 2003;26:602‐605.
    1. Centers for Disease Control and Prevention (CDC) . Update: severe respiratory illness associated with Middle East respiratory syndrome coronavirus (MERS‐CoV)‐worldwide, 2012‐2013. MMWR Morb Mortal Wkly Rep. 2013;62:480‐483.
    1. Maslow JN. Vaccines for emerging infectious diseases: lessons from MERS coronavirus and Zika virus. Hum Vaccin Immunother. 2017;13:2918‐2930.
    1. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS‐CoV): a systematic review and meta‐analysis. Int J Infect Dis. 2016;49:129‐133.
    1. Saad M, Omrani AS, Baig K, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single‐center experience in Saudi Arabia. Int J Infect Dis. 2014;29:301‐306.
    1. Al‐Abdallat MM, Payne DC, Alqasrawi S, et al. Hospital‐associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis. 2014;59:1225‐1233.
    1. Alhogbani T. Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus. Ann Saudi Med. 2016;36:78‐80.
    1. Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal influenza infections and cardiovascular disease mortality. AMA Cardiol. 2016;1:274‐281.
    1. Madjid M, Connolly AT, Nabutovsky Y, Safavi‐Naeini P, Razavi M, Miller CC. Effect of high influenza activity on risk of ventricular arrhythmias requiring therapy in patients with implantable cardiac defibrillators and cardiac resynchronization therapy defibrillators. Am J Cardiol. 2019;124:44‐50.
    1. Ang LW, Yap J, Lee V, et al. Influenza‐associated hospitalizations for cardiovascular diseases in the tropics. Am J Epidemiol. 2017;186:202‐209.
    1. Modin D, Jørgensen ME, Gislason G, et al. Influenza vaccine in heart failure. Circulation. 2019;139:575‐586.
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497‐506.
    1. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID‐19). JAMA Cardiol. 2020. 10.1001/jamacardio.2020.1017
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054‐1062.
    1. Li SS, Cheng C, Fu C, et al. Left ventricular performance in patients with severe acute respiratory syndrome: a 30‐day echocardiographic follow‐up study. Circulation. 2003;108:1798‐1803.
    1. Harris JE, Shah PJ, Korimilli V, Win H. Frequency of troponin elevations in patients with influenza infection during the 2017‐2018 influenza season. Int J Cardiol Heart Vasc. 2019;22:145‐147.
    1. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID‐19) infection: a systematic review and meta‐analysis. Int J Infect Dis. 2020. 10.1016/j.ijid.2020.03.017
    1. Zheng YY, Ma YT, Zhang JY, Xie X. COVID‐19 and the cardiovascular system. Nat Rev Cardiol. 2020. 10.1038/s41569-020-0360-5
    1. Oudit GY, Kassiri Z, Jiang C, et al. SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SAR. Eur J Clin Invest. 2009;39:618‐625.
    1. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136:95‐103.
    1. Cameron MJ, Bermejo‐Martin JF, Danesh A, Muller MP, Kelvin DJ. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res. 2008;133:13‐19.
    1. Yang C, Jin Z. An acute respiratory infection runs into the most common noncommunicable epidemic—COVID‐19 and cardiovascular diseases. JAMA Cardiol. 2020. 10.1001/jamacardio.2020.0934
    1. Ratliff NB, Estes ML, McMahon JT, Myles JL. Chloroquine‐induced cardiomyopathy. Arch Pathol Lab Med. 1988;112:578.
    1. Seshadri MS, John L, Varkey K, Koshy TS. Ventricular tachycardia in a patient on dehydroemetine and chloroquine for amoebic liver abscess. Med J Aust. 1979;1:406‐407.
    1. Fauchier JP, Fauchier L, Babuty D, Breuillac JC, Cosnay P, Rouesnel P. Drug‐induced ventricular tachycardia. Arch Mal Coeur Vaiss. 1993;86:757‐767.
    1. Siqueira‐Batista R, Ramos Júnior AN, Pessanha BS, Sforza‐de‐Almeida MP, Potsch DF. Chloroquine and cardiac arrhythmia: case report. East Afr Med J. 1998;75:117‐119.
    1. Harris L, Downar E, Shaikh NA, Chen T. Antiarrhythmic potential of chloroquine: new use for an old drug. Can J Cardiolo. 1988;4:295‐300.
    1. Verny C, de Gennes C, Sebastien P, et al. Heart conduction disorders in long‐term treatment with chloroquine: two new cases. Presse Med. 1992;2:800‐804.
    1. Capel RA, Herring N, Kalla M, et al. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization‐activated current if: novel electrophysiological insights and therapeutic potential. Heart Rhythm. 2015;12:2186‐2194.
    1. O'Laughlin JP, Mehta PH, Wong BC. Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. Case Rep Cardiol. 2016:4626279.
    1. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1986‐1994.
    1. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short‐term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801‐2809.
    1. Al‐Tawfiq JA, Hinedi K, Ghandour J, et al. Middle East respiratory syndrome coronavirus: a case‐control study of hospitalized patients. Clin Infect Dis. 2014;59:160‐165.
    1. Schoen K, Horvat N, Guerreiro NFC, de Castro I, de Giassi KS. Spectrum of clinical and radiographic findings in patients with diagnosis of H1N1 and correlation with clinical severity. BMC Infect Dis. 2019;19:964.
    1. Assiri A, Al‐Tawfiq JA, Al‐Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13:752‐761.
    1. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID‐19). JAMA Cardiol. 2020. 10.1001/jamacardio.2020.1096

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren